Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 7/20 | 0.53 |
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23588102 | 0.97 | SPHK1 (0.48) | SPHK1SPHK2S1PR1S1PR5 | |
| SCHEMBL25801985 | 0.89 | HDAC8 (0.43) | SPHK1S1PR1S1PR3S1PR5 | |
| SCHEMBL23588077 | 0.87 | ACACB (0.52) | S1PR1S1PR3 | |
| SCHEMBL25801979 | 0.86 | S1PR4 (0.44) | S1PR1S1PR3S1PR5 | |
| SCHEMBL25801811 | 0.86 | ALDH1A1 (0.37) | SPHK1 | |
| SCHEMBL23588068 | 0.85 | SPHK2 (0.42) | SPHK1SPHK2 | |
| SCHEMBL23588257 | 0.85 | SPHK1 (0.58) | SPHK1SPHK2S1PR1S1PR2S1PR3 | |
| SCHEMBL25801988 | 0.85 | SPHK1 (0.45) | SPHK1 | |
| SCHEMBL25802137 | 0.84 | MAPT (0.50) | — | |
| SCHEMBL23588349 | 0.83 | TP53 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| EP-4081511-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | Sitryx Therapeutics Limited (GB) | 2022-11-02 | — | — | EP | disclosed |
| CN-115066418-A | Carboxy derivatives with anti-inflammatory properties | 西特瑞治疗有限公司 | 2022-09-16 | — | — | CN | disclosed |
| WO-2021130492-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | CPA2, RO60, C5AR1 | SPHK1 3875/4885SPHK2 3631/4885S1PR1 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.